Evidence map›Paper›PMID 31159439›Full record

ReviewJournal of clinical medicine2019

MaioRegen Osteochondral Substitute for the Treatment of Knee Defects: A Systematic Review of the Literature.

Riccardo D'Ambrosi, Federico Valli, Paola De Luca, Nicola Ursino, Federico Giuseppe Usuelli

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Recombinant Human Amelogenin Protein Enhances Healing of Osteochondral Injury in a Goat Model.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026
    Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. The treatment of knee cartilage lesions: state of the art.Acta bio-medica : Atenei Parmensis · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Riccardo D'AmbrosiCASCO Department, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy. riccardo.dambrosi@hotmail.it.ORCID 0000-0002-1216-792X
Federico ValliCASCO Department, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy. mail@federicovalli.it.
Paola De LucaOrthopaedic Biotechnology Lab, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy. deluca.paola@grupposandonato.it.
Nicola UrsinoCASCO Department, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy. nicolaursino@libero.it.
Federico Giuseppe UsuelliCASCO Department, IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy. fusuelli@gmail.com.ORCID 0000-0003-2795-6603

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aims to investigate the clinical and radiological efficacy of three-dimensional acellular scaffolds (MaioRegen) in restoring osteochondral knee defects.

methodsMEDLINE, Scopus, CINAHL, Embase, and Cochrane Databases were searched for articles in which patients were treated with MaioRegen for osteochondral knee defects.

resultsA total of 471 patients were included in the study (mean age 34.07 ± 5.28 years). The treatment involved 500 lesions divided as follows: 202 (40.4%) medial femoral condyles, 107 (21.4%) lateral femoral condyles, 28 (5.6%) tibial plateaus, 46 (9.2%) trochleas, 74 (14.8%) patellas, and 43 (8.6%) unspecified femoral condyles. Mean lesion size was 3.6 ± 0.85 cm

conclusionThis systematic review describes the current available evidence for the treatment of osteochondral knee defects with MaioRegen Osteochondral substitute reporting promising satisfactory and reliable results at mid-term follow-up. A low rate of complications and failure was reported, confirming the safety of this scaffold. Considering the low level of evidence of the study included in the review, this data does not support the superiority of the Maioregen in terms of clinical improvement at follow-up compared to conservative treatment or other cartilage techniques.

Indexed as

cartilagegraftMaioRegenosteochondral defectosteochondral substitutescaffold

Identifiers

PMID31159439
PMCPMC6617307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.